A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles
Identifieur interne : 002454 ( Main/Exploration ); précédent : 002453; suivant : 002455A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles
Auteurs : R. Bannemerschult [Allemagne] ; J. P. Hanker [Allemagne] ; C. Wünsch [Allemagne] ; P. Fox [Allemagne] ; M. Albring [Allemagne] ; K. Brill [Allemagne]Source :
- Contraception [ 0010-7824 ] ; 1997.
Abstract
The aim of the trial was to demonstrate the contraceptive efficacy of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel and to observe cycle control and safety. Data from 805 treated women resulted in 4400 treatment cycles. One pregnancy occurred while on the trial medication as a result of method failure, resulting in a Pearl index of 0.29. Cycle control was good, and cycle length as well as duration and intensity of withdrawal bleeding were not significantly changed during the trial. Intermenstrual bleeding usually occurred as spotting and decreased considerably during the treatment phase. Spotting alone was reported in 12.4% of cycles, breakthrough bleeding alone in 4.5% of cycles, and breakthrough bleeding and spotting together in 1.4% of treatment cycles. The rate of absence of withdrawal bleeding declined throughout the trial to 2.4% in cycle 6. There were no serious adverse events related to treatment, and most adverse events were those commonly observed in clinical trials with oral contraceptives. Headache, breast tension, and nausea were reported by 17.3%, 11.0%, and 7.7% of the women, respectively. There were no clinically relevant changes in laboratory parameters, blood pressure, or weight. In this trial, the new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel was shown to be effective, safe, and well tolerated. Cycle control was found to be good and there was a low incidence of adverse events.
Url:
DOI: 10.1016/S0010-7824(97)00157-1
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001049
- to stream Istex, to step Curation: 000F39
- to stream Istex, to step Checkpoint: 000F26
- to stream Main, to step Merge: 002889
- to stream Main, to step Curation: 002454
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles</title><author><name sortKey="Bannemerschult, R" sort="Bannemerschult, R" uniqKey="Bannemerschult R" first="R." last="Bannemerschult">R. Bannemerschult</name></author><author><name sortKey="Hanker, J P" sort="Hanker, J P" uniqKey="Hanker J" first="J. P." last="Hanker">J. P. Hanker</name></author><author><name sortKey="Wunsch, C" sort="Wunsch, C" uniqKey="Wunsch C" first="C." last="Wünsch">C. Wünsch</name></author><author><name sortKey="Fox, P" sort="Fox, P" uniqKey="Fox P" first="P." last="Fox">P. Fox</name></author><author><name sortKey="Albring, M" sort="Albring, M" uniqKey="Albring M" first="M." last="Albring">M. Albring</name></author><author><name sortKey="Brill, K" sort="Brill, K" uniqKey="Brill K" first="K." last="Brill">K. Brill</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:703BB529C9960DFFF15F67B3AD6A580DF371FBDB</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0010-7824(97)00157-1</idno><idno type="url">https://api.istex.fr/document/703BB529C9960DFFF15F67B3AD6A580DF371FBDB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001049</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001049</idno><idno type="wicri:Area/Istex/Curation">000F39</idno><idno type="wicri:Area/Istex/Checkpoint">000F26</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F26</idno><idno type="wicri:doubleKey">0010-7824:1997:Bannemerschult R:a:multicenter:uncontrolled</idno><idno type="wicri:Area/Main/Merge">002889</idno><idno type="wicri:Area/Main/Curation">002454</idno><idno type="wicri:Area/Main/Exploration">002454</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles</title><author><name sortKey="Bannemerschult, R" sort="Bannemerschult, R" uniqKey="Bannemerschult R" first="R." last="Bannemerschult">R. Bannemerschult</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Schering AG, German Operations, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Hanker, J P" sort="Hanker, J P" uniqKey="Hanker J" first="J. P." last="Hanker">J. P. Hanker</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Obstetrics, Krankenanstalten der Mutter der Borromaerinnen, Trier</wicri:regionArea><wicri:noRegion>Trier</wicri:noRegion><wicri:noRegion>Trier</wicri:noRegion></affiliation></author><author><name sortKey="Wunsch, C" sort="Wunsch, C" uniqKey="Wunsch C" first="C." last="Wünsch">C. Wünsch</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Schering AG, German Operations, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Fox, P" sort="Fox, P" uniqKey="Fox P" first="P." last="Fox">P. Fox</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Schering AG, German Operations, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Albring, M" sort="Albring, M" uniqKey="Albring M" first="M." last="Albring">M. Albring</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Schering AG, German Operations, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Brill, K" sort="Brill, K" uniqKey="Brill K" first="K." last="Brill">K. Brill</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Schering AG, German Operations, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Contraception</title><title level="j" type="abbrev">CON</title><idno type="ISSN">0010-7824</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">56</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="285">285</biblScope><biblScope unit="page" to="290">290</biblScope></imprint><idno type="ISSN">0010-7824</idno></series><idno type="istex">703BB529C9960DFFF15F67B3AD6A580DF371FBDB</idno><idno type="DOI">10.1016/S0010-7824(97)00157-1</idno><idno type="PII">S0010-7824(97)00157-1</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0010-7824</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of the trial was to demonstrate the contraceptive efficacy of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel and to observe cycle control and safety. Data from 805 treated women resulted in 4400 treatment cycles. One pregnancy occurred while on the trial medication as a result of method failure, resulting in a Pearl index of 0.29. Cycle control was good, and cycle length as well as duration and intensity of withdrawal bleeding were not significantly changed during the trial. Intermenstrual bleeding usually occurred as spotting and decreased considerably during the treatment phase. Spotting alone was reported in 12.4% of cycles, breakthrough bleeding alone in 4.5% of cycles, and breakthrough bleeding and spotting together in 1.4% of treatment cycles. The rate of absence of withdrawal bleeding declined throughout the trial to 2.4% in cycle 6. There were no serious adverse events related to treatment, and most adverse events were those commonly observed in clinical trials with oral contraceptives. Headache, breast tension, and nausea were reported by 17.3%, 11.0%, and 7.7% of the women, respectively. There were no clinically relevant changes in laboratory parameters, blood pressure, or weight. In this trial, the new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel was shown to be effective, safe, and well tolerated. Cycle control was found to be good and there was a low incidence of adverse events.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Bannemerschult, R" sort="Bannemerschult, R" uniqKey="Bannemerschult R" first="R." last="Bannemerschult">R. Bannemerschult</name></region><name sortKey="Albring, M" sort="Albring, M" uniqKey="Albring M" first="M." last="Albring">M. Albring</name><name sortKey="Brill, K" sort="Brill, K" uniqKey="Brill K" first="K." last="Brill">K. Brill</name><name sortKey="Fox, P" sort="Fox, P" uniqKey="Fox P" first="P." last="Fox">P. Fox</name><name sortKey="Hanker, J P" sort="Hanker, J P" uniqKey="Hanker J" first="J. P." last="Hanker">J. P. Hanker</name><name sortKey="Wunsch, C" sort="Wunsch, C" uniqKey="Wunsch C" first="C." last="Wünsch">C. Wünsch</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002454 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002454 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:703BB529C9960DFFF15F67B3AD6A580DF371FBDB
|texte= A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles
}}
| This area was generated with Dilib version V0.6.31. |  |